Estropipate


CAS No. : 7280-37-7

(Synonyms: Piperazine estrone sulfate; Estrone sulfate piperazine salt)

7280-37-7
Price and Availability of CAS No. : 7280-37-7
Size Price Stock
5mg $32 In-stock
10mg $50 In-stock
50mg $100 In-stock
100mg $150 In-stock
500mg $450 In-stock
1 g Get quote
5 g Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-B1361
M.Wt: 436.56
Formula: C22H32N2O5S
Purity: >98 %
Solubility: DMSO : 110 mg/mL (ultrasonic)
Introduction of 7280-37-7 :

Estropipate (Piperazine estrone sulfate; Estrone sulfate piperazine salt) is an inactive endogenous estrogen that can be converted into Estrone (HY-B0234) and Estradiol (HY-B0141). Estropipate is an orally active estrogen receptor α agonist and a selective OATP1B1 inhibitor. Estropipate inhibits OATP1B1-mediated uptake of statin substrates. Estropipate regulates the estrogen signaling pathway and ameliorates sensory processing and arousal-related behavioral deficits in scn1lab-mutant zebrafish. Estropipate can be used in studies related to autism[1][2]. In Vitro: Estropipate (EPP) potently and selectively inhibits OATP1B1-mediated transport of Rosuvastatin (HY-17504A) in humans and cynomolgus monkeys, with IC50 values of 0.05 μM and 0.12 μM, respectively, while only exerting weak inhibitory effects on other hepatic uptake transporters[2].
Estropipate (1-100 μM; 0.25-5 minutes) selectively inhibits OATP1B1-mediated uptake of statins into human and cynomolgus monkey hepatocytes at a concentration of 1 μM, an effect that accounts for 44%-64% of the total hepatic uptake clearance of Rosuvastatin, Pitavastatin (HY-B0144A), and dehydrated Pravastatin; in contrast, Estropipate at 100 μM inhibits uptake mediated by all of OATP1B1, OATP1B3, OATP2B1, and NTCP[2]. In Vivo: Estropipate (EST) (10 μM; continuous water exposure; 5 to 7 days post-fertilization) acts as a potent inhibitor of autism spectrum disorder (ASD)-related behavioral phenotypes in scn1lab mutants, and reverses 12 out of 18 abnormal baseline parameters, including daytime resting episode frequency[1].
Estropipate (EPP) (0.3-6 mg/kg; p.o.; single administration; 1 hour prior to Rosuvastatin administration) dose-dependently increases the systemic exposure of Rosuvastatin in cynomolgus monkeys, and its mechanism of action is the selective inhibition of OATP1B1-mediated hepatic uptake[2].

Your information is safe with us.